Poseida Therapeutics, Inc. (PSTX)
NASDAQ: PSTX · Real-Time Price · USD
2.760
+0.040 (1.47%)
Nov 21, 2024, 12:04 PM EST - Market open
Poseida Therapeutics Employees
Poseida Therapeutics had 330 employees as of December 31, 2023. The number of employees increased by 16 or 5.10% compared to the previous year.
Employees
330
Change (1Y)
16
Growth (1Y)
5.10%
Revenue / Employee
$457,145
Profits / Employee
-$184,118
Market Cap
269.00M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accolade | 2,400 |
AngioDynamics | 748 |
Vanda Pharmaceuticals | 203 |
NeuroPace | 171 |
Mersana Therapeutics | 123 |
Atea Pharmaceuticals | 75 |
Rezolute | 59 |
Artiva Biotherapeutics | 43 |
PSTX News
- 7 days ago - Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline - PRNewsWire
- 9 days ago - Poseida Therapeutics to Present at Two Upcoming Investor Conferences - PRNewsWire
- 13 days ago - Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024 - PRNewsWire
- 15 days ago - Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024 - PRNewsWire
- 4 weeks ago - Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema - PRNewsWire
- 5 weeks ago - Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche - PRNewsWire
- 6 weeks ago - Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024 - PRNewsWire
- 7 weeks ago - Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement - Seeking Alpha